Form 4: Xtant Medical Director Awarded 158,228 Deferred Stock Units

Xtant Medical Holdings, Inc. director Tyler Lipschultz received a deferred stock unit award of 158,228 shares, vesting in November 2026.

Summary

• Tyler Lipschultz, a director of Xtant Medical Holdings, Inc. (XTNT), was granted 158,228 deferred stock units (DSUs).
• The transaction date for this award was November 15, 2025.
• These DSUs were granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan.
• Each DSU represents a contingent right to receive one share of the Issuer's common stock.
• The shares are subject to a vesting condition, requiring Mr. Lipschultz to remain a director of Xtant through the vesting date of November 15, 2026.
• Settlement of the vested shares will be deferred and occur at a later date as per the DSU award agreement.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued director commitment and aligns interests with shareholders through equity compensation, a standard practice.

Positives

• The award aligns the director's interests with long-term shareholder value through equity compensation.
• The use of the Amended and Restated 2023 Equity Incentive Plan demonstrates a structured approach to executive and director compensation.

Negatives

• The director does not receive immediate liquidity from this award, as settlement is deferred and vesting is conditioned on continued service.

Risks

• The vesting of the 158,228 shares is conditioned upon the reporting person remaining a director of Xtant through November 15, 2026.
• The value of the shares upon settlement is subject to the future market price of Xtant Medical Holdings, Inc. common stock.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an insider's equity award.

Industry Context

This is a routine insider transaction disclosure, reflecting standard equity compensation practices for directors in publicly traded companies within the medical device or healthcare industry. It does not provide broader industry trends or competitive insights.

Corporate Governance

Stakeholder Impact

• Shareholders: The award aligns the director's financial interests with the company's long-term performance, potentially benefiting shareholders through motivated leadership.
• Employees: This filing does not directly impact employees, but it reflects the company's overall compensation strategy for key personnel.

Next Steps

• Tyler Lipschultz must remain a director of Xtant Medical Holdings, Inc. until November 15, 2026, for the DSUs to vest.
• The vested shares will be settled at a later, deferred date according to the DSU award agreement.

Key Dates

Keywords

Xtant Medical Holdings, XTNT, Deferred Stock Units, DSU, Insider Transaction, Equity Incentive Plan, Director Compensation, Stock Award, Vesting